A phase II study of trastuzumab added to docetaxel and S-1 for human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer.
Phase 2
- Conditions
- gastric cancer
- Registration Number
- JPRN-UMIN000005366
- Lead Sponsor
- Okayama University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) with severe allergy to Trastuzumab, S-1 and docetaxel 2) Active infection or other inflammatory disease 3) synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ 4) Other severe complications such as paralytic ileus, intestinal pneumonitis, pulmonary fibrosis, uncontrollable diabetes millutus, hypertension, and respiratory insufficiency. 5) History of cardiac disease 6) Dyspnea at rest, due to complications of advanced malignancy or other cardiovascular disease 7) Metastasis to CNS 8) Grade 3-4 peripheral sensory neuropathy 9) pregnant or nursing patient or with intent to bear baby 10) Inappropriate for the trial at the physician's assessment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method